Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Ionis Pharmaceuticals but lowers the price target from $70 to $65.
October 09, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guggenheim maintains a Buy rating on Ionis Pharmaceuticals but reduces the price target from $70 to $65, indicating a slightly less optimistic outlook.
The maintained Buy rating suggests continued confidence in Ionis Pharmaceuticals, but the lowered price target indicates a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100